Back to search results

UNIFY: Collecting Samples for Cancer Research

This study, called UNIFY, is collecting blood and tissue samples from people at Yale Cancer Center. It's for patients with a suspected or confirmed solid tumor or blood cancer, or those at high risk for cancer due to genetics or other factors. The goal is to build a large collection of samples for current and future research into cancer. This study is observational, meaning it involves collecting information and samples without giving any new treatments. The main goal is to collect and organize these samples for up to 5 years. The current status of the study is unclear.

Study design
This is an observational study planning to enroll 2500 participants. It involves collecting samples for research.
What's involved
You would provide blood samples and dried blood spots, and potentially archival tissue. These samples will be collected through the study's completion, up to 5 years.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07689864

Unified Network for Integrated Fluid Collection at Yale

Recruiting
Not specifiedAges 18+Observational
Yale University
~2,500 participants
Updated 2026-08-25 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Collection and annotation of biospecimens
Measured over Through study completion, up to 5 years

Conditions

Molecular Residual Disease
Cancer

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT07689864

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Smilow Cancer Hospital

    New Haven, Connecticutno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mitchell Elliott, MD · PRINCIPAL_INVESTIGATOR · Yale University
  • Maryam Lustberg, MD, MPH · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Mitchell Elliott, MD
[email protected]
475-375-7981
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and/or significant family history of malignancy).
Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY.
If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence.

Exclusion

Inability to provide informed consent.
Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).

What this trial measures

  • Collection and annotation of biospecimensThrough study completion, up to 5 years

    Facilitate and streamline the collection, banking, and clinical annotation of liquid biopsy biospecimens (peripheral blood collected in Streck Cell-Free DNA BCT® tubes or blood spots) - and, optionally, corresponding archival tumor specimens - for cancer research studies across Yale Cancer Center and the Smilow Cancer Hospital network.